HomeAgenda

ProductUpdated on 17 September 2025

Partnership opportunity: Phase 1 ready personalized cancer vaccine

About

YG-01 is a fully individualized neoantigen based cancer vaccine designed to prevent tumor recurrence post surgery. 

Neoantigens are identified with our proprietary YGNITE™ neoantigen discovery platform and coupled to our vaccine technology CARGONAUT™ to uniquely target and activate immune cells. 

  • In vivo proof-of-concept demonstrated

  • GLP toxicology completed

  • GMP manufacture completed

  • Clinical Trial entry in H1 2026 in Glioblastoma

Why partner with YGION?

  • Phase 1 ready asset:  Preclinical proof-of-concept, completed GLP toxicology and GMP manufacture complete for YG-01

  • Lean development plan to indicators of clinical efficacy within 3 years

  • Patent protected proprietary and differentiated neoantigen vaccine technologies 

  • Application across multiple cancer types: with multi $B market opportunity

  • Experienced team:  Management and advisory co-founder team with extensive biotech/Pharma leadership experience

We welcome the opportunity to meet with partners for collaboration, co-development or out-licensing partners in Japan and other global markets

Organisation

YGION Biomedical GmbH

Company (SME/startup) / 中小企業・スタートアップ

Wien, Austria